Moreover, upon co-incubation of non-CAR engineered T lymphocytes and CAR expressing T cells with KRASG12V NCI-H441, we observed only low-level IFN-γ release by both anti-KRASG12V-IgFc and anti-KRASG12V-STII CAR T cells (Fig. 4A) [41, 42], suggesting a putatively low concentration of KRASG12V/HLA-A2 complexes expressed on the NCI-H441 tumor target. This evidence concerns the gene IFNG and neoplasm.